BofA lowered the firm’s price target on Aardvark Therapeutics (AARD) to $18 from $20 and keeps a Buy rating on the shares. The firm updated the company’s model post the Q1 report.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AARD:
- Aardvark Therapeutics reports Q1 EPS (99c), consensus (91c)
- Options Volatility and Implied Earnings Moves Today, April 06, 2026
- Options Volatility and Implied Earnings Moves This Week, April 06 – April 10, 2026
- AARD Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Aardvark Therapeutics price target lowered to $8 from $32 at B. Riley